Gyre Therapeutics, Inc. (GYRE)
USD 6.95
(2.13%)
USD 6.95
(2.13%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 199 Thousand USD | 64.46% |
| 2022 | 121 Thousand USD | -70.34% |
| 2021 | 408 Thousand USD | -58.41% |
| 2020 | 981 Thousand USD | -25.63% |
| 2019 | 1.31 Million USD | 0.0% |
| 2018 | - USD | 0.0% |
| 2017 | - USD | 0.0% |
| 2016 | - USD | 0.0% |
| 2015 | - USD | 0.0% |
| 2014 | - USD | -100.0% |
| 2013 | 283 Thousand USD | -75.09% |
| 2012 | 1.13 Million USD | -42.8% |
| 2011 | 1.98 Million USD | 47.22% |
| 2010 | 1.34 Million USD | -31.38% |
| 2009 | 1.96 Million USD | -42.31% |
| 2008 | 3.4 Million USD | 102.15% |
| 2007 | 1.68 Million USD | 106.58% |
| 2006 | 816.07 Thousand USD | -42.1% |
| 2005 | 1.4 Million USD | -59.07% |
| 2004 | 3.44 Million USD | 135.52% |
| 2003 | 1.46 Million USD | -29.98% |
| 2002 | 2.08 Million USD | 0.0% |
| 2001 | - USD | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q2 | 1.29 Million USD | 0.0% |
| 2024 Q1 | 175 Thousand USD | 0.0% |
| 2023 Q4 | 199 Thousand USD | 0.0% |
| 2023 FY | 199 Thousand USD | 64.46% |
| 2023 Q2 | 2618.63 USD | -97.86% |
| 2023 Q3 | 199 Thousand USD | 7499.39% |
| 2023 Q1 | 122.34 Thousand USD | 1.11% |
| 2022 FY | 121 Thousand USD | -70.34% |
| 2022 Q1 | - USD | -100.0% |
| 2022 Q2 | - USD | 0.0% |
| 2022 Q4 | 121 Thousand USD | 0.0% |
| 2022 Q3 | 121 Thousand USD | 0.0% |
| 2021 FY | 408 Thousand USD | -58.41% |
| 2021 Q1 | 806 Thousand USD | -17.84% |
| 2021 Q4 | 408 Thousand USD | -25.82% |
| 2021 Q3 | 550 Thousand USD | -47.82% |
| 2021 Q2 | 1.05 Million USD | 30.77% |
| 2020 Q3 | 925 Thousand USD | -12.65% |
| 2020 Q1 | 1.19 Million USD | -9.7% |
| 2020 Q2 | 1.05 Million USD | -11.08% |
| 2020 Q4 | 981 Thousand USD | 6.05% |
| 2020 FY | 981 Thousand USD | -25.63% |
| 2019 FY | 1.31 Million USD | 0.0% |
| 2019 Q4 | 1.31 Million USD | -8.59% |
| 2019 Q3 | 1.44 Million USD | -7.85% |
| 2019 Q1 | 1.68 Million USD | 0.0% |
| 2019 Q2 | 1.56 Million USD | -7.12% |
| 2018 Q2 | - USD | 0.0% |
| 2018 Q4 | - USD | 0.0% |
| 2018 FY | - USD | 0.0% |
| 2018 Q3 | - USD | 0.0% |
| 2018 Q1 | - USD | 0.0% |
| 2017 Q3 | - USD | 0.0% |
| 2017 Q1 | - USD | 0.0% |
| 2017 FY | - USD | 0.0% |
| 2017 Q4 | - USD | 0.0% |
| 2017 Q2 | - USD | 0.0% |
| 2016 Q4 | - USD | 0.0% |
| 2016 Q2 | - USD | 0.0% |
| 2016 Q1 | - USD | 0.0% |
| 2016 FY | - USD | 0.0% |
| 2016 Q3 | - USD | 0.0% |
| 2015 Q3 | - USD | 0.0% |
| 2015 Q4 | - USD | 0.0% |
| 2015 Q2 | - USD | 0.0% |
| 2015 Q1 | - USD | 0.0% |
| 2015 FY | - USD | 0.0% |
| 2014 Q1 | 142 Thousand USD | -49.82% |
| 2014 Q3 | - USD | 0.0% |
| 2014 Q4 | - USD | 0.0% |
| 2014 FY | - USD | -100.0% |
| 2014 Q2 | - USD | -100.0% |
| 2013 Q3 | 478 Thousand USD | -31.62% |
| 2013 FY | 283 Thousand USD | -75.09% |
| 2013 Q4 | 283 Thousand USD | -40.79% |
| 2013 Q2 | 699 Thousand USD | -23.86% |
| 2013 Q1 | 918 Thousand USD | -19.19% |
| 2012 Q4 | 1.13 Million USD | -15.91% |
| 2012 FY | 1.13 Million USD | -42.8% |
| 2012 Q1 | 1.77 Million USD | -10.57% |
| 2012 Q2 | 1.56 Million USD | -11.94% |
| 2012 Q3 | 1.35 Million USD | -13.62% |
| 2011 FY | 1.98 Million USD | 47.22% |
| 2011 Q2 | 2.43 Million USD | 164.39% |
| 2011 Q3 | 2.19 Million USD | -9.86% |
| 2011 Q1 | 921 Thousand USD | -31.73% |
| 2011 Q4 | 1.98 Million USD | -9.52% |
| 2010 Q3 | 1.83 Million USD | 51.28% |
| 2010 FY | 1.34 Million USD | -31.38% |
| 2010 Q1 | 1.59 Million USD | -18.97% |
| 2010 Q2 | 1.21 Million USD | -23.73% |
| 2010 Q4 | 1.34 Million USD | -26.61% |
| 2009 Q4 | 1.96 Million USD | -15.73% |
| 2009 Q2 | 2.69 Million USD | -11.76% |
| 2009 FY | 1.96 Million USD | -42.31% |
| 2009 Q3 | 2.33 Million USD | -13.43% |
| 2009 Q1 | 3.05 Million USD | -10.39% |
| 2008 Q2 | 3.69 Million USD | -7.71% |
| 2008 Q1 | 4 Million USD | 137.5% |
| 2008 FY | 3.4 Million USD | 102.15% |
| 2008 Q4 | 3.4 Million USD | -9.27% |
| 2008 Q3 | 3.75 Million USD | 1.65% |
| 2007 FY | 1.68 Million USD | 106.58% |
| 2007 Q1 | 656.8 Thousand USD | -19.52% |
| 2007 Q4 | 1.68 Million USD | -11.44% |
| 2007 Q3 | 1.9 Million USD | -9.22% |
| 2007 Q2 | 2.09 Million USD | 219.29% |
| 2006 Q2 | 1.12 Million USD | -12.03% |
| 2006 Q1 | 1.28 Million USD | -9.07% |
| 2006 FY | 816.07 Thousand USD | -42.1% |
| 2006 Q3 | 972.91 Thousand USD | -13.7% |
| 2006 Q4 | 816.07 Thousand USD | -16.12% |
| 2005 FY | 1.4 Million USD | -59.07% |
| 2005 Q4 | 1.4 Million USD | 0.0% |
| 2004 FY | 3.44 Million USD | 135.52% |
| 2003 FY | 1.46 Million USD | -29.98% |
| 2002 FY | 2.08 Million USD | 0.0% |
| 2001 FY | - USD | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| AbCellera Biologics Inc. | 71.22 Million USD | 99.721% |
| Alkermes plc | 287.73 Million USD | 99.931% |
| Agenus Inc. | 137.32 Million USD | 99.855% |
| Alnylam Pharmaceuticals, Inc. | 2.34 Billion USD | 99.992% |
| Aptorum Group Limited | 3.05 Million USD | 93.494% |
| Ardelyx, Inc. | 51.54 Million USD | 99.614% |
| Arrowhead Pharmaceuticals, Inc. | 104.6 Million USD | 99.81% |
| Bicycle Therapeutics plc | 40.08 Million USD | 99.503% |
| BioXcel Therapeutics, Inc. | 100.59 Million USD | 99.802% |
| ChromaDex Corporation | 2.57 Million USD | 92.272% |
| Chimerix, Inc. | 125 Thousand USD | -59.2% |
| Corbus Pharmaceuticals Holdings, Inc. | 3.23 Million USD | 93.855% |
| Caribou Biosciences, Inc. | 25.9 Million USD | 99.232% |
| CRISPR Therapeutics AG | 223 Million USD | 99.911% |
| Precision BioSciences, Inc. | 7.72 Million USD | 97.423% |
| Dyadic International, Inc. | 88.87 Thousand USD | -123.923% |
| Eton Pharmaceuticals, Inc. | 22 Thousand USD | -804.545% |
| Fortress Biotech, Inc. | 60.85 Million USD | 99.673% |
| Lantern Pharma Inc. | 61.49 Thousand USD | -223.598% |
| HOOKIPA Pharma Inc. | 3.8 Million USD | 94.765% |
| Inhibikase Therapeutics, Inc. | 90.12 Thousand USD | -120.807% |
| Incyte Corporation | 29.16 Million USD | 99.318% |
| IO Biotech, Inc. | 1.83 Million USD | 89.179% |
| Jaguar Health, Inc. | 30.99 Million USD | 99.358% |
| Novavax, Inc. | 168.01 Million USD | 99.882% |
| Janux Therapeutics, Inc. | 23.02 Million USD | 99.136% |
| Opthea Limited | 200.53 Million USD | 99.901% |
| Ligand Pharmaceuticals Incorporated | 5.75 Million USD | 96.542% |
| ContextLogic Inc. | 6 Million USD | 96.683% |
| MiMedx Group, Inc. | 48.09 Million USD | 99.586% |
| Pyxis Oncology, Inc. | 20.09 Million USD | 99.01% |
| TransCode Therapeutics, Inc. | 38.29 Thousand USD | -419.704% |
| NextCure, Inc. | 5.94 Million USD | 96.655% |
| Ocuphire Pharma, Inc. | - USD | -Infinity% |
| Oncternal Therapeutics, Inc. | 145 Thousand USD | -37.241% |
| Outlook Therapeutics, Inc. | - USD | -Infinity% |
| Vaxcyte, Inc. | 22.11 Million USD | 99.1% |
| PDS Biotechnology Corporation | 19.5 Million USD | 98.98% |
| Madrigal Pharmaceuticals, Inc. | 115.48 Million USD | 99.828% |
| Pharming Group N.V. | 166.1 Million USD | 99.88% |
| Pieris Pharmaceuticals, Inc. | - USD | -Infinity% |
| Avidity Biosciences, Inc. | 6.21 Million USD | 96.797% |
| Reviva Pharmaceuticals Holdings, Inc. | - USD | -Infinity% |
| Reviva Pharmaceuticals Holdings, Inc. | - USD | -Infinity% |
| Sangamo Therapeutics, Inc. | 33.51 Million USD | 99.406% |
| Sol-Gel Technologies Ltd. | 1.2 Million USD | 83.499% |
| Acelyrin, Inc. | 1.19 Million USD | 83.333% |
| Salarius Pharmaceuticals, Inc. | - USD | -Infinity% |
| SELLAS Life Sciences Group, Inc. | 460 Thousand USD | 56.739% |
| Summit Therapeutics Inc. | 103.29 Million USD | 99.807% |
| Sensei Biotherapeutics, Inc. | 3.76 Million USD | 94.72% |
| Senti Biosciences, Inc. | 33.53 Million USD | 99.407% |
| Stoke Therapeutics, Inc. | 4.77 Million USD | 95.831% |
| Syros Pharmaceuticals, Inc. | 34.55 Million USD | 99.424% |
| Alaunos Therapeutics, Inc. | - USD | -Infinity% |
| Telomir Pharmaceuticals, Inc. Common Stock | - USD | -Infinity% |
| Entrada Therapeutics, Inc. | 60.32 Million USD | 99.67% |
| VistaGen Therapeutics, Inc. | 1.57 Million USD | 87.325% |
| Wave Life Sciences Ltd. | 25.4 Million USD | 99.217% |
| Sorrento Therapeutics, Inc. | 104.33 Million USD | 99.809% |
| TRACON Pharmaceuticals, Inc. | 732 Thousand USD | 72.814% |
| Barinthus Biotherapeutics plc | 11.19 Million USD | 98.222% |
| Psyence Biomedical Ltd. | - USD | -Infinity% |
| Phathom Pharmaceuticals, Inc. | 138.3 Million USD | 99.856% |
| Immix Biopharma, Inc. | - USD | -Infinity% |
| Keros Therapeutics, Inc. | 13.43 Million USD | 98.519% |
| MEI Pharma, Inc. | - USD | -Infinity% |
| Windtree Therapeutics, Inc. | 15 Million USD | 98.673% |
| Xeris Biopharma Holdings, Inc. | 190.93 Million USD | 99.896% |
| Rigel Pharmaceuticals, Inc. | 52.65 Million USD | 99.622% |
| Fortress Biotech, Inc. | 60.85 Million USD | 99.673% |
| Precigen, Inc. | 5.89 Million USD | 96.624% |
| Clearside Biomedical, Inc. | 41.98 Million USD | 99.526% |
| AlloVir, Inc. | 16.64 Million USD | 98.805% |
| C4 Therapeutics, Inc. | 65.75 Million USD | 99.697% |
| Fate Therapeutics, Inc. | 97.36 Million USD | 99.796% |
| ImmuCell Corporation | 10.54 Million USD | 98.112% |
| IDEAYA Biosciences, Inc. | 1.12 Million USD | 82.311% |
| Onconetix, Inc. | 118.85 Thousand USD | -67.428% |
| PureTech Health plc | 18.25 Million USD | 98.91% |
| VYNE Therapeutics Inc. | 99 Thousand USD | -101.01% |
| Elevation Oncology, Inc. | 30.13 Million USD | 99.34% |
| Kintara Therapeutics, Inc. | - USD | -Infinity% |
| Seer, Inc. | 25.96 Million USD | 99.234% |
| Verrica Pharmaceuticals Inc. | 42.87 Million USD | 99.536% |
| Innoviva, Inc. | 446.23 Million USD | 99.955% |
| Aadi Bioscience, Inc. | 833 Thousand USD | 76.11% |
| ESSA Pharma Inc. | - USD | -Infinity% |
| GlycoMimetics, Inc. | 66.84 Thousand USD | -197.708% |
| GT Biopharma, Inc. | - USD | -Infinity% |
| Inhibrx Biosciences, Inc. | 206.96 Million USD | 99.904% |
| Akebia Therapeutics, Inc. | 71.19 Million USD | 99.72% |
| Catalyst Pharmaceuticals, Inc. | 3.18 Million USD | 93.758% |
| Longboard Pharmaceuticals, Inc. | - USD | -Infinity% |
| Orchestra BioMed Holdings, Inc. | 1.03 Million USD | 80.829% |
| Alzamend Neuro, Inc. | - USD | -Infinity% |
| Rocket Pharmaceuticals, Inc. | 22.32 Million USD | 99.109% |
| Aptose Biosciences Inc. | 621 Thousand USD | 67.955% |
| ZyVersa Therapeutics, Inc. | - USD | -Infinity% |
| Soligenix, Inc. | 1.01 Million USD | 80.315% |
| Century Therapeutics, Inc. | 46.65 Million USD | 99.573% |
| Kura Oncology, Inc. | 9.33 Million USD | 97.868% |
| TScan Therapeutics, Inc. | 26.7 Million USD | 99.255% |
| Intensity Therapeutics, Inc. | 138 Thousand USD | -44.203% |
| Ocean Biomedical, Inc. | - USD | -Infinity% |
| CytomX Therapeutics, Inc. | 9.38 Million USD | 97.88% |
| Autolus Therapeutics plc | 47.91 Million USD | 99.585% |
| Mineralys Therapeutics, Inc. | - USD | -Infinity% |
| EyePoint Pharmaceuticals, Inc. | 4.9 Million USD | 95.944% |
| Eterna Therapeutics Inc. | 6.77 Million USD | 97.062% |
| Adaptive Biotechnologies Corporation | 130.66 Million USD | 99.848% |
| GRI Bio, Inc. | - USD | -Infinity% |
| Xenetic Biosciences, Inc. | - USD | -Infinity% |
| Tenaya Therapeutics, Inc. | 8.1 Million USD | 97.545% |
| IGM Biosciences, Inc. | 34.67 Million USD | 99.426% |
| INmune Bio, Inc. | 397 Thousand USD | 49.874% |
| Heron Therapeutics, Inc. | 173.75 Million USD | 99.885% |
| SAB Biotherapeutics, Inc. | 4.05 Million USD | 95.092% |
| Pasithea Therapeutics Corp. | - USD | -Infinity% |
| Entero Therapeutics, Inc. | 146.94 Thousand USD | -35.421% |
| Milestone Pharmaceuticals Inc. | 49.77 Million USD | 99.6% |
| X4 Pharmaceuticals, Inc. | 54.57 Million USD | 99.635% |
| Atara Biotherapeutics, Inc. | 45.69 Million USD | 99.564% |
| Coherus BioSciences, Inc. | 473.36 Million USD | 99.958% |
| Verastem, Inc. | 40.08 Million USD | 99.504% |
| Abeona Therapeutics Inc. | 4.4 Million USD | 95.479% |
| Pliant Therapeutics, Inc. | 10.05 Million USD | 98.021% |
| Tonix Pharmaceuticals Holding Corp. | 6.56 Million USD | 96.967% |
| Histogen Inc. | 4.38 Million USD | 95.461% |
| Aprea Therapeutics, Inc. | - USD | -Infinity% |
| Surrozen, Inc. | 882 Thousand USD | 77.438% |
| Organovo Holdings, Inc. | 888 Thousand USD | 77.59% |
| Lixte Biotechnology Holdings, Inc. | - USD | -Infinity% |
| Ovid Therapeutics Inc. | 30 Million USD | 99.337% |
| Panbela Therapeutics, Inc. | 4.19 Million USD | 95.255% |
| CASI Pharmaceuticals, Inc. | 18.89 Million USD | 98.947% |
| Cadrenal Therapeutics, Inc. Common Stock | - USD | -Infinity% |
| Centessa Pharmaceuticals plc | 75.7 Million USD | 99.737% |
| Hepion Pharmaceuticals, Inc. | 93.1 Thousand USD | -113.739% |
| Arcturus Therapeutics Holdings Inc. | 25.9 Million USD | 99.232% |
| BioRestorative Therapies, Inc. | - USD | -Infinity% |
| Apollomics, Inc. | 267 Thousand USD | 25.468% |
| Amarin Corporation plc | 8.73 Million USD | 97.722% |
| Mesoblast Limited | 100.48 Million USD | 99.802% |
| Turnstone Biologics Corp. | 1.18 Million USD | 83.263% |
| Kymera Therapeutics, Inc. | 78.32 Million USD | 99.746% |
| Synaptogenix, Inc. | - USD | -Infinity% |
| Tiziana Life Sciences Ltd | 109 Thousand USD | -82.569% |
| Aurinia Pharmaceuticals Inc. | 82 Million USD | 99.757% |
| BriaCell Therapeutics Corp. | - USD | -Infinity% |
| Monopar Therapeutics Inc. | - USD | -Infinity% |
| Exelixis, Inc. | 189.94 Million USD | 99.895% |
| Better Therapeutics, Inc. | 10.34 Million USD | 98.077% |
| Nurix Therapeutics, Inc. | 23.12 Million USD | 99.139% |
| Apellis Pharmaceuticals, Inc. | 93.03 Million USD | 99.786% |
| NLS Pharmaceutics AG | - USD | -Infinity% |
| Dermata Therapeutics, Inc. | - USD | -Infinity% |
| Aridis Pharmaceuticals, Inc. | 1.29 Million USD | 84.598% |
| Gritstone bio, Inc. | 40.14 Million USD | 99.504% |
| Jasper Therapeutics, Inc. | 1.81 Million USD | 89.03% |
| TNF Pharmaceuticals, Inc. | - USD | -Infinity% |
| Avid Bioservices, Inc. | 153.59 Million USD | 99.87% |
| Insmed Incorporated | 1.19 Billion USD | 99.983% |
| Virpax Pharmaceuticals, Inc. | - USD | -Infinity% |
| MediWound Ltd. | 6.35 Million USD | 96.866% |
| OmniAb, Inc. | 22.07 Million USD | 99.099% |
| Alector, Inc. | 30.45 Million USD | 99.347% |
| Seres Therapeutics, Inc. | 101.54 Million USD | 99.804% |
| Checkpoint Therapeutics, Inc. | - USD | -Infinity% |
| Viracta Therapeutics, Inc. | - USD | -Infinity% |
| Zai Lab Limited | 8.04 Million USD | 97.527% |
| Revance Therapeutics, Inc. | 426.59 Million USD | 99.953% |
| Aura Biosciences, Inc. | 16.87 Million USD | 98.82% |
| Lyell Immunopharma, Inc. | 56.89 Million USD | 99.65% |
| Immunic, Inc. | 639 Thousand USD | 68.858% |
| Tarsus Pharmaceuticals, Inc. | 29.81 Million USD | 99.333% |
| Veracyte, Inc. | 7.52 Million USD | 97.355% |
| InMed Pharmaceuticals Inc. | 644.86 Million USD | 99.969% |
| FibroGen, Inc. | 89.69 Million USD | 99.778% |
| SeaStar Medical Holding Corporation | 4.33 Million USD | 95.412% |
| Adial Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sonnet BioTherapeutics Holdings, Inc. | 130.86 Thousand USD | -52.067% |
| Jazz Pharmaceuticals plc | 5.1 Billion USD | 99.996% |
| Cyclacel Pharmaceuticals, Inc. | 37 Thousand USD | -437.838% |
| Amylyx Pharmaceuticals, Inc. | 1.98 Million USD | 89.949% |
| TG Therapeutics, Inc. | 100.11 Million USD | 99.801% |
| Galecto, Inc. | 66 Thousand USD | -201.515% |
| Calithera Biosciences, Inc. | 136 Thousand USD | -46.324% |
| Fortrea Holdings Inc. | 1.63 Billion USD | 99.988% |
| KalVista Pharmaceuticals, Inc. | 6.01 Million USD | 96.692% |
| Aptevo Therapeutics Inc. | 5.39 Million USD | 96.313% |
| XBiotech Inc. | - USD | -Infinity% |
| Jasper Therapeutics, Inc. | 1.81 Million USD | 89.03% |
| Lyra Therapeutics, Inc. | 21.44 Million USD | 99.072% |
| Foghorn Therapeutics Inc. | 36.55 Million USD | 99.456% |
| Y-mAbs Therapeutics, Inc. | 517 Thousand USD | 61.509% |
| Theravance Biopharma, Inc. | 45.23 Million USD | 99.56% |
| Ultragenyx Pharmaceutical Inc. | 30.57 Million USD | 99.349% |
| Metagenomi, Inc. Common Stock | 44.8 Million USD | 99.556% |
| Vaxxinity, Inc. | 13.26 Million USD | 98.499% |
| BioCryst Pharmaceuticals, Inc. | 811.26 Million USD | 99.975% |
| Gain Therapeutics, Inc. | 449.05 Thousand USD | 55.685% |
| Cartesian Therapeutics, Inc. | 8.78 Million USD | 97.736% |
| NexImmune, Inc. | - USD | -Infinity% |
| Creative Medical Technology Holdings, Inc. | - USD | -Infinity% |
| Marker Therapeutics, Inc. | - USD | -Infinity% |
| Regeneron Pharmaceuticals, Inc. | 2.7 Billion USD | 99.993% |
| Chemomab Therapeutics Ltd. | 316 Thousand USD | 37.025% |
| Scopus BioPharma Inc. | - USD | -Infinity% |
| RAPT Therapeutics, Inc. | 4.45 Million USD | 95.536% |
| Ainos, Inc. | 5.92 Million USD | 96.639% |
| Pluri Inc. | 29.05 Million USD | 99.315% |
| Prothena Corporation plc | 10.72 Million USD | 98.144% |
| Adaptimmune Therapeutics plc | 19.85 Million USD | 98.998% |
| Celularity Inc. | 26.17 Million USD | 99.24% |
| Rallybio Corporation | 173 Thousand USD | -15.029% |
| Cue Biopharma, Inc. | 4.2 Million USD | 95.264% |
| MeiraGTx Holdings plc | 72.11 Million USD | 99.724% |
| Omeros Corporation | 329.7 Million USD | 99.94% |
| Humacyte, Inc. | 38.6 Million USD | 99.484% |
| Immunocore Holdings plc | 82.64 Million USD | 99.759% |
| Cocrystal Pharma, Inc. | 1.61 Million USD | 87.663% |
| Cidara Therapeutics, Inc. | 3.57 Million USD | 94.437% |
| Blueprint Medicines Corporation | 610.96 Million USD | 99.967% |
| CalciMedica, Inc. | - USD | -Infinity% |
| Cabaletta Bio, Inc. | 1.45 Million USD | 86.351% |
| Marinus Pharmaceuticals, Inc. | 95.18 Million USD | 99.791% |
| Scholar Rock Holding Corporation | 48.68 Million USD | 99.591% |
| Sana Biotechnology, Inc. | 90.9 Million USD | 99.781% |
| Pulmatrix, Inc. | 8.32 Million USD | 97.61% |
| Elicio Therapeutics, Inc. | 6 Million USD | 96.687% |
| Vigil Neuroscience, Inc. | 12.94 Million USD | 98.463% |
| Intellia Therapeutics, Inc. | 96.74 Million USD | 99.794% |
| Adlai Nortye Ltd. American Depositary Shares | 469 Thousand USD | 57.569% |
| Cytokinetics, Incorporated | 607.37 Million USD | 99.967% |
| Eloxx Pharmaceuticals, Inc. | 8.69 Million USD | 97.711% |
| Nutriband Inc. | 79.82 Thousand USD | -149.292% |
| Protara Therapeutics, Inc. | 4.48 Million USD | 95.562% |
| Vor Biopharma Inc. | 31.83 Million USD | 99.375% |
| Roivant Sciences Ltd. | 477.85 Million USD | 99.958% |
| Evogene Ltd. | 10.65 Million USD | 98.132% |
| ProKidney Corp. | 3.61 Million USD | 94.488% |
| Applied Therapeutics, Inc. | 759 Thousand USD | 73.781% |
| Hoth Therapeutics, Inc. | 26.32 Thousand USD | -655.907% |
| BridgeBio Pharma, Inc. | 1.73 Billion USD | 99.989% |
| CorMedix Inc. | 517.01 Thousand USD | 61.51% |
| BioLineRx Ltd. | 6.62 Million USD | 96.998% |
| Tango Therapeutics, Inc. | 36.83 Million USD | 99.46% |
| Galectin Therapeutics Inc. | 71.74 Million USD | 99.723% |
| Atai Life Sciences N.V. | 15.21 Million USD | 98.692% |
| Renovaro Biosciences Inc. | 842.38 Thousand USD | 76.377% |
| Aerovate Therapeutics, Inc. | 255 Thousand USD | 21.961% |
| Zentalis Pharmaceuticals, Inc. | 43.15 Million USD | 99.539% |
| Sagimet Biosciences Inc. | - USD | -Infinity% |
| MediciNova, Inc. | 410.66 Thousand USD | 51.541% |
| Praxis Precision Medicines, Inc. | 1.36 Million USD | 85.464% |
| Cardio Diagnostics Holdings, Inc. | 663.09 Thousand USD | 69.989% |
| GeoVax Labs, Inc. | - USD | -Infinity% |
| Axsome Therapeutics, Inc. | 178.07 Million USD | 99.888% |
| Biomea Fusion, Inc. | 7.83 Million USD | 97.458% |
| PTC Therapeutics, Inc. | 284.21 Million USD | 99.93% |
| Mereo BioPharma Group plc | 5.3 Million USD | 96.245% |
| Cullinan Oncology, Inc. | 2.15 Million USD | 90.744% |
| Syndax Pharmaceuticals, Inc. | 588 Thousand USD | 66.156% |
| Absci Corporation | 4.66 Million USD | 95.73% |
| NRx Pharmaceuticals, Inc. | - USD | -Infinity% |
| 4D Molecular Therapeutics, Inc. | 11.52 Million USD | 98.273% |
| Dyne Therapeutics, Inc. | 22.69 Million USD | 99.123% |
| Kiniksa Pharmaceuticals, Ltd. | 10 Million USD | 98.011% |
| Ventyx Biosciences, Inc. | 11.5 Million USD | 98.27% |
| Allakos Inc. | 38.21 Million USD | 99.479% |
| Imunon, Inc. | 1.13 Million USD | 82.533% |
| Fulcrum Therapeutics, Inc. | 8.62 Million USD | 97.694% |
| Corcept Therapeutics Incorporated | - USD | -Infinity% |
| BioAtla, Inc. | 836 Thousand USD | 76.196% |
| NLS Pharmaceutics AG | - USD | -Infinity% |
| Bio-Path Holdings, Inc. | 10 Thousand USD | -1890.0% |
| Allogene Therapeutics, Inc. | 88.34 Million USD | 99.775% |
| Larimar Therapeutics, Inc. | 4.7 Million USD | 95.774% |
| XOMA Corporation | 118.51 Million USD | 99.832% |
| Kezar Life Sciences, Inc. | 10.06 Million USD | 98.024% |
| Cara Therapeutics, Inc. | 37.07 Million USD | 99.463% |
| aTyr Pharma, Inc. | 13.76 Million USD | 98.555% |
| Aligos Therapeutics, Inc. | 7.89 Million USD | 97.481% |
| Akero Therapeutics, Inc. | 24.96 Million USD | 99.203% |
| Viridian Therapeutics, Inc. | 20.2 Million USD | 99.015% |
| Eliem Therapeutics, Inc. | 15 Thousand USD | -1226.667% |
| EyeGate Pharmaceuticals, Inc. | 278.19 Thousand USD | 28.466% |
| Akari Therapeutics, Plc | - USD | -Infinity% |
| Tevogen Bio Holdings Inc. | 14.45 Million USD | 98.623% |
| Halozyme Therapeutics, Inc. | 1.49 Billion USD | 99.987% |
| Lexaria Bioscience Corp. | 136.17 Thousand USD | -46.138% |
| UroGen Pharma Ltd. | 98.55 Million USD | 99.798% |
| Sutro Biopharma, Inc. | 149.11 Million USD | 99.867% |
| ZIVO Bioscience, Inc. | - USD | -Infinity% |
| Orgenesis Inc. | 19.06 Million USD | 98.956% |
| Entera Bio Ltd. | 256 Thousand USD | 22.266% |
| GH Research PLC | 631 Thousand USD | 68.463% |
| Lisata Therapeutics, Inc. | 137.00 USD | -145155.474% |
| Reneo Pharmaceuticals, Inc. | 642 Thousand USD | 69.003% |
| Xencor, Inc. | 14.64 Million USD | 98.641% |
| 60 Degrees Pharmaceuticals, Inc. | 150.25 Thousand USD | -32.445% |
| Replimune Group, Inc. | 71.99 Million USD | 99.724% |
| Coeptis Therapeutics Holdings, Inc. | 150 Thousand USD | -32.667% |
| Vanda Pharmaceuticals Inc. | 7 Million USD | 97.16% |
| Lexaria Bioscience Corp. | 136.17 Thousand USD | -46.138% |
| Portage Biotech Inc. | 7000.00 USD | -2742.857% |
| Cardio Diagnostics Holdings, Inc. | 663.09 Thousand USD | 69.989% |
| Olema Pharmaceuticals, Inc. | 1.42 Million USD | 86.074% |
| OncoCyte Corporation | 2.2 Million USD | 90.971% |
| Qualigen Therapeutics, Inc. | - USD | -Infinity% |
| Processa Pharmaceuticals, Inc. | 66.9 Thousand USD | -197.437% |
| Purple Biotech Ltd. | 163 Thousand USD | -22.086% |
| CollPlant Biotechnologies Ltd. | 2.53 Million USD | 92.15% |
| scPharmaceuticals Inc. | 38.81 Million USD | 99.487% |
| ProMIS Neurosciences, Inc. | - USD | -Infinity% |
| HilleVax, Inc. | 25.24 Million USD | 99.212% |
| NeuroSense Therapeutics Ltd. | 73 Thousand USD | -172.603% |
| Tharimmune, Inc. | - USD | -Infinity% |
| Genprex, Inc. | - USD | -Infinity% |
| Neumora Therapeutics, Inc. Common Stock | 1.85 Million USD | 89.261% |
| Atossa Therapeutics, Inc. | - USD | -Infinity% |
| XTL Biopharmaceuticals Ltd. | - USD | -Infinity% |
| Virios Therapeutics, Inc. | - USD | -Infinity% |
| OKYO Pharma Limited | - USD | -Infinity% |
| Savara Inc. | 26.34 Million USD | 99.245% |
| Curis, Inc. | 1.48 Million USD | 86.635% |
| Daré Bioscience, Inc. | 3.91 Million USD | 94.915% |
| Carmell Therapeutics Corporation | 697.71 Thousand USD | 71.478% |
| Titan Pharmaceuticals, Inc. | - USD | -Infinity% |
| Achieve Life Sciences, Inc. | 6000.00 USD | -3216.667% |
| BeiGene, Ltd. | 197.61 Million USD | 99.899% |
| Kiromic BioPharma, Inc. | 911.5 Thousand USD | 78.168% |
| Revolution Medicines, Inc. Warrant | 80.57 Million USD | 99.753% |
| Protagonist Therapeutics, Inc. | - USD | -Infinity% |
| Erasca, Inc. | 51.88 Million USD | 99.616% |
| bluebird bio, Inc. | 224.41 Million USD | 99.911% |
| Protagenic Therapeutics, Inc. | - USD | -Infinity% |
| BioMarin Pharmaceutical Inc. | 593.09 Million USD | 99.966% |
| DBV Technologies S.A. | 4.52 Million USD | 95.603% |
| Protagenic Therapeutics, Inc. | - USD | -Infinity% |
| Moderna, Inc. | - USD | -Infinity% |
| Vincerx Pharma, Inc. | 1.34 Million USD | 85.149% |
| Fresh Tracks Therapeutics, Inc. | - USD | -Infinity% |
| Molecular Templates, Inc. | 9.74 Million USD | 97.957% |
| Acrivon Therapeutics, Inc. Common Stock | 3.76 Million USD | 94.717% |
| Travere Therapeutics, Inc. | 377.26 Million USD | 99.947% |
| Monte Rosa Therapeutics, Inc. | 42.87 Million USD | 99.536% |
| Spruce Biosciences, Inc. | 1.71 Million USD | 88.41% |
| Celldex Therapeutics, Inc. | 928 Thousand USD | 78.556% |
| Cogent Biosciences, Inc. | 17.46 Million USD | 98.861% |
| MacroGenics, Inc. | 30.19 Million USD | 99.341% |
| RenovoRx, Inc. | - USD | -Infinity% |
| Adicet Bio, Inc. | 17.7 Million USD | 98.876% |
| Prime Medicine, Inc. | 4.35 Million USD | 95.433% |
| Aditxt, Inc. | 1.04 Million USD | 80.897% |
| Adagene Inc. | 13.54 Million USD | 98.53% |
| Estrella Immunopharma, Inc. | - USD | -Infinity% |
| Quantum-Si incorporated | 13.73 Million USD | 98.551% |
| Maravai LifeSciences Holdings, Inc. | 518.7 Million USD | 99.962% |
| Acurx Pharmaceuticals, Inc. | - USD | -Infinity% |
| Voyager Therapeutics, Inc. | 17.09 Million USD | 98.836% |
| SciSparc Ltd. | 24 Thousand USD | -729.167% |
| Vericel Corporation | 81.85 Million USD | 99.757% |
| Revelation Biosciences, Inc. | - USD | -Infinity% |
| Minerva Neurosciences, Inc. | 82.01 Million USD | 99.757% |
| Generation Bio Co. | 89.77 Million USD | 99.778% |
| Astria Therapeutics, Inc. | - USD | -Infinity% |
| Black Diamond Therapeutics, Inc. | 22.18 Million USD | 99.103% |
| Arcutis Biotherapeutics, Inc. | 201.79 Million USD | 99.901% |
| Invivyd, Inc. | 722 Thousand USD | 72.438% |
| Relay Therapeutics, Inc. | 48.5 Million USD | 99.59% |
| Quoin Pharmaceuticals, Ltd. | 2923.73 USD | -6706.374% |
| Spero Therapeutics, Inc. | 3.82 Million USD | 94.797% |
| Artelo Biosciences, Inc. | 23 Thousand USD | -765.217% |
| 2seventy bio, Inc. | 244.01 Million USD | 99.918% |
| ADMA Biologics, Inc. | 130.59 Million USD | 99.848% |
| Clene Inc. | 7.15 Million USD | 97.218% |
| Capricor Therapeutics, Inc. | 3.37 Million USD | 94.106% |
| Boundless Bio, Inc. Common Stock | 247.61 Million USD | 99.92% |
| GeoVax Labs, Inc. | - USD | -Infinity% |
| Recursion Pharmaceuticals, Inc. | 1.1 Million USD | 81.926% |
| Citius Pharmaceuticals, Inc. | 262.86 Thousand USD | 24.296% |
| Contineum Therapeutics, Inc. Class A Common Stock | 192.62 Million USD | 99.897% |
| Relmada Therapeutics, Inc. | - USD | -Infinity% |
| Finch Therapeutics Group, Inc. | 28.4 Million USD | 99.299% |
| ALX Oncology Holdings Inc. | 9.63 Million USD | 97.935% |
| Vir Biotechnology, Inc. | 111.67 Million USD | 99.822% |
| Evaxion Biotech A/S | 8.48 Million USD | 97.656% |
| Ocular Therapeutix, Inc. | 74.92 Million USD | 99.734% |
| Verve Therapeutics, Inc. | 64.71 Million USD | 99.692% |
| Trevena, Inc. | 35.23 Million USD | 99.435% |
| Surrozen, Inc. | 882 Thousand USD | 77.438% |
| Tyra Biosciences, Inc. | 6.21 Million USD | 96.799% |
| Cingulate Inc. | 135.09 Thousand USD | -47.299% |
| Galmed Pharmaceuticals Ltd. | - USD | -Infinity% |
| Unity Biotechnology, Inc. | 23.53 Million USD | 99.155% |
| Tenax Therapeutics, Inc. | - USD | -Infinity% |
| Terns Pharmaceuticals, Inc. | - USD | -Infinity% |
| ACADIA Pharmaceuticals Inc. | 47.8 Million USD | 99.584% |
| Connect Biopharma Holdings Limited | 180 Thousand USD | -10.556% |
| Clearmind Medicine Inc. | - USD | -Infinity% |
| Kronos Bio, Inc. | 25.37 Million USD | 99.216% |
| Bolt Biotherapeutics, Inc. | 17.43 Million USD | 98.859% |
| CERo Therapeutics Holdings, Inc. | - USD | -Infinity% |
| Viking Therapeutics, Inc. | 936 Thousand USD | 78.739% |
| Statera Biopharma, Inc. | 11.43 Million USD | 98.259% |
| ImmunityBio, Inc. | 836.95 Million USD | 99.976% |
| Korro Bio, Inc. | 31.21 Million USD | 99.363% |
| Kineta, Inc. | 150 Thousand USD | -32.667% |
| BioVie Inc. | 349.89 Thousand USD | 43.126% |
| Codexis, Inc. | 12.24 Million USD | 98.375% |
| Celularity Inc. | 26.17 Million USD | 99.24% |
| Crinetics Pharmaceuticals, Inc. | 47.55 Million USD | 99.582% |
| Celcuity Inc. | 37.03 Million USD | 99.463% |
| Virax Biolabs Group Limited | 176.34 Thousand USD | -12.847% |
| Cibus, Inc. | 17.67 Million USD | 98.874% |
| Eledon Pharmaceuticals, Inc. | - USD | -Infinity% |
| eFFECTOR Therapeutics, Inc. | - USD | -Infinity% |
| IN8bio, Inc. | 3.37 Million USD | 94.111% |
| Kodiak Sciences Inc. | 100 Million USD | 99.801% |
| Annexon, Inc. | 29.19 Million USD | 99.318% |
| Adverum Biotechnologies, Inc. | 64.62 Million USD | 99.692% |
| Assembly Biosciences, Inc. | 1.12 Million USD | 82.264% |
| Avalo Therapeutics, Inc. | 2 Million USD | 90.05% |
| Ionis Pharmaceuticals, Inc. | 1.4 Billion USD | 99.986% |
| Eyenovia, Inc. | 8.95 Million USD | 97.778% |
| Puma Biotechnology, Inc. | 65.65 Million USD | 99.697% |
| Conduit Pharmaceuticals Inc. | - USD | -Infinity% |
| Xilio Therapeutics, Inc. | 8.14 Million USD | 97.556% |
| Arcellx, Inc. | 50.84 Million USD | 99.609% |
| Cardiff Oncology, Inc. | 1.45 Million USD | 86.351% |
| Enanta Pharmaceuticals, Inc. | 21.23 Million USD | 99.063% |
| Regulus Therapeutics Inc. | 1.05 Million USD | 81.137% |
| Moolec Science SA | 99.04 Thousand USD | -100.917% |
| Acumen Pharmaceuticals, Inc. | 27.62 Million USD | 99.28% |
| Geron Corporation | 35.05 Million USD | 99.432% |
| LAVA Therapeutics N.V. | 591 Thousand USD | 66.328% |
| Royalty Pharma plc | 6.13 Billion USD | 99.997% |
| Atea Pharmaceuticals, Inc. | 1.64 Million USD | 87.881% |
| Greenwich LifeSciences, Inc. | - USD | -Infinity% |
| TFF Pharmaceuticals, Inc. | 31.74 Thousand USD | -526.93% |
| Mersana Therapeutics, Inc. | 23.14 Million USD | 99.14% |
| Humacyte, Inc. | 38.6 Million USD | 99.484% |
| Structure Therapeutics Inc. | 4.01 Million USD | 95.041% |
| 89bio, Inc. | 24.79 Million USD | 99.197% |
| PMV Pharmaceuticals, Inc. | 12.43 Million USD | 98.4% |
| Avenue Therapeutics, Inc. | - USD | -Infinity% |
| Genelux Corporation | 1.86 Million USD | 89.335% |
| Trevi Therapeutics, Inc. | 1.03 Million USD | 80.717% |
| Lexicon Pharmaceuticals, Inc. | 99.5 Million USD | 99.8% |
| Notable Labs, Ltd. | 1.52 Million USD | 86.959% |
| Liquidia Corporation | 2.36 Million USD | 91.582% |
| Mustang Bio, Inc. | 1.97 Million USD | 89.939% |
| Immunovant, Inc. | - USD | -Infinity% |
| Quantum-Si incorporated | 13.73 Million USD | 98.551% |
| Arbutus Biopharma Corporation | 6.95 Million USD | 97.138% |
| DiaMedica Therapeutics Inc. | 317 Thousand USD | 37.224% |
| Vera Therapeutics, Inc. | 49.87 Million USD | 99.601% |
| Acasti Pharma Inc. | - USD | -Infinity% |
| MiNK Therapeutics, Inc. | - USD | -Infinity% |
| Pasithea Therapeutics Corp. | - USD | -Infinity% |
| Xenon Pharmaceuticals Inc. | 9.6 Million USD | 97.928% |
| Elevai Labs, Inc. Common Stock | 65.48 Thousand USD | -203.868% |
| NeuroBo Pharmaceuticals, Inc. | 136 Thousand USD | -46.324% |
| Tempest Therapeutics, Inc. | 6.26 Million USD | 96.823% |
| Soleno Therapeutics, Inc. | 130 Thousand USD | -53.077% |
| PepGen Inc. | 17.1 Million USD | 98.836% |
| Moleculin Biotech, Inc. | 474 Thousand USD | 58.017% |
| United Therapeutics Corporation | 300 Million USD | 99.934% |
| Nuvectis Pharma, Inc. | - USD | -Infinity% |
| Solid Biosciences Inc. | 23.94 Million USD | 99.169% |
| BriaCell Therapeutics Corp. | - USD | -Infinity% |
| Immuneering Corporation | 4.16 Million USD | 95.22% |
| Lixte Biotechnology Holdings, Inc. | - USD | -Infinity% |
| Silo Pharma, Inc. | - USD | -Infinity% |
| Belite Bio, Inc | 578 Thousand USD | 65.571% |
| XOMA Corporation | 118.51 Million USD | 99.832% |
| ARS Pharmaceuticals, Inc. | 37 Thousand USD | -437.838% |
| Bionomics Limited | 117.62 Million USD | 99.831% |
| Apogee Therapeutics, Inc. | 933 Thousand USD | 78.671% |
| Alpha Tau Medical Ltd. | 5.61 Million USD | 96.453% |
| uniQure N.V. | 130.06 Million USD | 99.847% |
| Cassava Sciences, Inc. | - USD | -Infinity% |
| Estrella Immunopharma, Inc. | - USD | -Infinity% |
| Poseida Therapeutics, Inc. | 58.59 Million USD | 99.66% |
| Forte Biosciences, Inc. | - USD | -Infinity% |
| Anebulo Pharmaceuticals, Inc. | - USD | -Infinity% |
| Enlivex Therapeutics Ltd. | 686 Thousand USD | 70.991% |
| Conduit Pharmaceuticals Inc. | - USD | -Infinity% |
| SeaStar Medical Holding Corporation | 4.33 Million USD | 95.412% |
| FibroBiologics, Inc. Common Stock | 1.38 Million USD | 85.632% |
| Altimmune, Inc. | 175 Thousand USD | -13.714% |
| Amicus Therapeutics, Inc. | 387.85 Million USD | 99.949% |
| Alpha Tau Medical Ltd. | 5.61 Million USD | 96.453% |
| Compugen Ltd. | 719 Thousand USD | 72.323% |
| Peak Bio, Inc. | - USD | -Infinity% |
| Zevra Therapeutics, Inc. | 5.06 Million USD | 96.072% |
| Benitec Biopharma Inc. | - USD | -Infinity% |
| Spyre Therapeutics, Inc. | 84.55 Million USD | 99.765% |
| NKGen Biotech, Inc. Common Stock | 9.93 Million USD | 97.996% |
| Zura Bio Limited | - USD | -Infinity% |
| PolyPid Ltd. | 6.37 Million USD | 96.88% |
| Aileron Therapeutics, Inc. | 91.41 Million USD | 99.782% |
| NKGen Biotech, Inc. Warrants | 9.93 Million USD | 97.996% |
| Instil Bio, Inc. | 81.42 Million USD | 99.756% |
| argenx SE | 15.35 Million USD | 98.704% |
| Immunome, Inc. | 1.34 Million USD | 85.149% |
| Compass Therapeutics, Inc. | 536 Thousand USD | 62.873% |
| Verona Pharma plc | 48.37 Million USD | 99.589% |
| enGene Holdings Inc. Warrants | 9.21 Million USD | 97.841% |
| Shattuck Labs, Inc. | 3.4 Million USD | 94.157% |
| CervoMed Inc. | - USD | -Infinity% |
| LENZ Therapeutics, Inc. | - USD | -Infinity% |
| Plus Therapeutics, Inc. | 85 Thousand USD | -134.118% |
| Dianthus Therapeutics, Inc. | 168 Thousand USD | -18.452% |
| Moolec Science SA | 99.04 Thousand USD | -100.917% |
| Enveric Biosciences, Inc. | - USD | -Infinity% |
| Inovio Pharmaceuticals, Inc. | 11.03 Million USD | 98.196% |
| AnaptysBio, Inc. | 16.03 Million USD | 98.759% |
| Design Therapeutics, Inc. | 2.33 Million USD | 91.474% |
| Leap Therapeutics, Inc. | - USD | -Infinity% |
| NeurAxis, Inc. | 27.07 Thousand USD | -635.104% |
| Seelos Therapeutics, Inc. | - USD | -Infinity% |
| Lumos Pharma, Inc. | 6 Million USD | 96.683% |
| Achilles Therapeutics plc | 1.07 Million USD | 81.506% |
| enGene Holdings Inc. Common Stock | 9.21 Million USD | 97.841% |
| 180 Life Sciences Corp. | 19.93 Thousand USD | -898.194% |
| Opiant Pharmaceuticals, Inc. | 16.74 Million USD | 98.811% |
| CERo Therapeutics Holdings, Inc. | - USD | -Infinity% |
| Nutriband Inc. | 79.82 Thousand USD | -149.292% |
| ORIC Pharmaceuticals, Inc. | 7461.00 USD | -2567.203% |
| CG Oncology, Inc. Common stock | 13 Thousand USD | -1430.769% |
| Fractyl Health, Inc. Common Stock | 342.48 Million USD | 99.942% |
| Rani Therapeutics Holdings, Inc. | 24.48 Million USD | 99.187% |
| MoonLake Immunotherapeutics | 2.49 Million USD | 92.04% |
| Palisade Bio, Inc. | 90 Thousand USD | -121.111% |
| Tourmaline Bio, Inc. | 194 Thousand USD | -2.577% |
| Beam Therapeutics Inc. | 159.91 Million USD | 99.876% |
| Neurogene Inc. | 13.37 Million USD | 98.512% |
| Mirum Pharmaceuticals, Inc. | 306.42 Million USD | 99.935% |
| AEON Biopharma, Inc. | - USD | -Infinity% |
| CARGO Therapeutics, Inc. Common Stock | 26.26 Million USD | 99.242% |
| Sesen Bio, Inc. | - USD | -Infinity% |
| Enliven Therapeutics, Inc. | - USD | -Infinity% |
| Kiora Pharmaceuticals, Inc. | 59.82 Thousand USD | -232.654% |
| Iovance Biotherapeutics, Inc. | 1 Million USD | 80.1% |
| Taysha Gene Therapies, Inc. | 40.5 Million USD | 99.509% |
| Athira Pharma, Inc. | 1.21 Million USD | 83.648% |
| Vaccinex, Inc. | 26 Thousand USD | -665.385% |
| HCW Biologics Inc. | 6.3 Million USD | 96.843% |
| XOMA Corporation | 118.51 Million USD | 99.832% |
| Nektar Therapeutics | 112.62 Million USD | 99.823% |
| Arvinas, Inc. | 800 Thousand USD | 75.125% |
| Tevogen Bio Holdings Inc. | 14.45 Million USD | 98.623% |
| Merus N.V. | 10.48 Million USD | 98.103% |
| Omega Therapeutics, Inc. | 14.88 Million USD | 98.663% |
| Quince Therapeutics, Inc. | 13.42 Million USD | 98.518% |
| Rezolute, Inc. | 1.66 Million USD | 88.012% |
| Clene Inc. | 7.15 Million USD | 97.218% |
| Indaptus Therapeutics, Inc. | 73.34 Thousand USD | -171.309% |
| BeyondSpring Inc. | 3.36 Million USD | 94.084% |
| Synlogic, Inc. | 12.49 Million USD | 98.407% |
| Allarity Therapeutics, Inc. | - USD | -Infinity% |
| Phio Pharmaceuticals Corp. | - USD | -Infinity% |
| Peak Bio, Inc. | - USD | -Infinity% |
| Werewolf Therapeutics, Inc. | 32.65 Million USD | 99.391% |
| Krystal Biotech, Inc. | 6.62 Million USD | 96.994% |
| Karyopharm Therapeutics Inc. | 170.91 Million USD | 99.884% |
| SpringWorks Therapeutics, Inc. | 5.99 Million USD | 96.681% |
| Lipella Pharmaceuticals Inc. | 47.37 Thousand USD | -320.088% |
| MannKind Corporation | 252.15 Million USD | 99.921% |
| Ikena Oncology, Inc. | 7.18 Million USD | 97.228% |
| Cyclerion Therapeutics, Inc. | - USD | -Infinity% |
| Gossamer Bio, Inc. | 197.4 Million USD | 99.899% |
| CohBar, Inc. | - USD | -Infinity% |
| Cognition Therapeutics, Inc. | 520 Thousand USD | 61.731% |
| NRx Pharmaceuticals, Inc. | - USD | -Infinity% |
| Legend Biotech Corporation | 281.32 Million USD | 99.929% |
| Mural Oncology plc | 8.91 Million USD | 97.767% |
| Biora Therapeutics, Inc. | 43.73 Million USD | 99.545% |
| PaxMedica, Inc. Common Stock | - USD | -Infinity% |
| Disc Medicine, Inc. | 1.43 Million USD | 86.142% |
| Champions Oncology, Inc. | 6.09 Million USD | 96.734% |
| REGENXBIO Inc. | 82.22 Million USD | 99.758% |
| Ensysce Biosciences, Inc. | - USD | -Infinity% |
| Anavex Life Sciences Corp. | - USD | -Infinity% |
| Cellectar Biosciences, Inc. | 494 Thousand USD | 59.717% |
| Edgewise Therapeutics, Inc. | 4.43 Million USD | 95.512% |
| Vaxart, Inc. | 2.62 Million USD | 92.413% |
| PharmaCyte Biotech, Inc. | - USD | -Infinity% |
| Aldeyra Therapeutics, Inc. | 271.63 Thousand USD | 26.739% |
| Cellectis S.A. | 36.24 Million USD | 99.451% |
| Longeveron Inc. | 1.44 Million USD | 86.257% |
| Repare Therapeutics Inc. | 1.01 Million USD | 80.297% |
| Sarepta Therapeutics, Inc. | 1.13 Billion USD | 99.982% |
| Inozyme Pharma, Inc. | 44.76 Million USD | 99.555% |
| Revolution Medicines, Inc. | 80.57 Million USD | 99.753% |
| Nymox Pharmaceutical Corporation | - USD | -Infinity% |
| Third Harmonic Bio, Inc. | 3.2 Million USD | 93.797% |
| ArriVent BioPharma, Inc. Common Stock | 177 Thousand USD | -12.429% |
| AN2 Therapeutics, Inc. | - USD | -Infinity% |
| Anixa Biosciences, Inc. | 123 Thousand USD | -61.789% |
| Vertex Pharmaceuticals Incorporated | 724.7 Million USD | 99.973% |
| Denali Therapeutics Inc. | 44.98 Million USD | 99.558% |
| Revelation Biosciences, Inc. | - USD | -Infinity% |
| Veru Inc. | 12.5 Million USD | 98.409% |
| Corvus Pharmaceuticals, Inc. | - USD | -Infinity% |
| Cingulate Inc. | 135.09 Thousand USD | -47.299% |
| Passage Bio, Inc. | 22.92 Million USD | 99.132% |
| Context Therapeutics Inc. | - USD | -Infinity% |
| Exicure, Inc. | 6.03 Million USD | 96.705% |
| Day One Biopharmaceuticals, Inc. | - USD | -Infinity% |
| Oramed Pharmaceuticals Inc. | 647 Thousand USD | 69.243% |
| Scinai Immunotherapeutics Ltd. | 20.16 Million USD | 99.013% |
| Rhythm Pharmaceuticals, Inc. | 490 Thousand USD | 59.388% |
| Nuvalent, Inc. | - USD | -Infinity% |
| ABVC BioPharma, Inc. | 407.45 Thousand USD | 51.16% |
| Carisma Therapeutics, Inc. | 1.18 Million USD | 83.249% |
| Unicycive Therapeutics, Inc. | 466 Thousand USD | 57.296% |
| OmniAb, Inc. | 22.07 Million USD | 99.099% |
| Anew Medical, Inc. | 1.54 Million USD | 87.078% |
| Fennec Pharmaceuticals Inc. | 29.55 Million USD | 99.327% |
| Lipocine Inc. | - USD | -Infinity% |
| Lexeo Therapeutics, Inc. Common Stock | 9.03 Million USD | 97.797% |
| Nautilus Biotechnology, Inc. | 31.09 Million USD | 99.36% |
| SAB Biotherapeutics, Inc. | 4.05 Million USD | 95.092% |
| G1 Therapeutics, Inc. | 51.55 Million USD | 99.614% |
| Bellerophon Therapeutics, Inc. | - USD | -Infinity% |
| Sage Therapeutics, Inc. | - USD | -Infinity% |
| Ocugen, Inc. | 6.36 Million USD | 96.875% |
| Mind Medicine (MindMed) Inc. | 14.12 Million USD | 98.592% |
| Q32 Bio Inc. | - USD | -Infinity% |
| Brainstorm Cell Therapeutics Inc. | 672 Thousand USD | 70.387% |
| Alumis Inc. Common Stock | 30.86 Million USD | 99.355% |
| Equillium, Inc. | 384 Thousand USD | 48.177% |
| Kyverna Therapeutics, Inc. | 6.15 Million USD | 96.769% |
| Coya Therapeutics, Inc. | - USD | -Infinity% |
| CNS Pharmaceuticals, Inc. | - USD | -Infinity% |
| Galera Therapeutics, Inc. | 151.04 Million USD | 99.868% |
| Evelo Biosciences, Inc. | 48.87 Million USD | 99.593% |
| Comera Life Sciences Holdings, Inc. | 120.3 Thousand USD | -65.417% |
| Dominari Holdings Inc. | 3.02 Million USD | 93.428% |
| Edesa Biotech, Inc. | 19.77 Thousand USD | -906.423% |
| vTv Therapeutics Inc. | 169 Thousand USD | -17.751% |
| Bio-Techne Corporation | 319 Million USD | 99.938% |
| Agios Pharmaceuticals, Inc. | 56.98 Million USD | 99.651% |
| Harmony Biosciences Holdings, Inc. | 178.56 Million USD | 99.889% |
| Prelude Therapeutics Incorporated | 15.4 Million USD | 98.708% |
| Candel Therapeutics, Inc. | 12.38 Million USD | 98.393% |
| iTeos Therapeutics, Inc. | 4.8 Million USD | 95.86% |
| Nkarta, Inc. | 82.27 Million USD | 99.758% |
| BioCardia, Inc. | 982 Thousand USD | 79.735% |
| Iterum Therapeutics plc | 18.95 Million USD | 98.95% |